TABLE 5.

Antibody levels in SOTRs and controls

Months	Comparison	Anti-N-IgG			Anti- S IgG
		Estimated ratio (%)	95% CI	p	Estimated ratio (%)	95% CI	p
1	Age <50 vs. ≥50	116.8	49.6–274.7	.720	250.3	86.0–728.3	.092
3	Age <50 vs. ≥50	101.9	60.9–170.4	.943	112.1	56.4–222.8	.743
6	Age <50 vs. ≥50	70.3	35.2–140.3	.315	83.9	40.8–172.6	.630
9	Age <50 vs. ≥50	87.3	49.8–153.2	.634	90.6	39.8–206.3	.814
1	Sex female vs. male	41.9	17.8–98.2	.045	41.7	14.2–122.0	.109
3	Sex female vs. male	95.0	56.3–160.1	.845	69.3	34.3–139.9	.304
6	Sex female vs. male	61.3	30.0–125.4	.178	110.7	53.1–230.9	.785
9	Sex female vs. male	100.6	57.4–176.1	.984	83.8	36.5–192.4	.675
1	Severity score 1 vs. 2–4	38.3	14.5–101.2	.053	7.9	2.3–27.4	<.001
3	Severity score 1 vs. 2–4	37.9	22.1–64.9	.001	16.3	7.9–33.8	<.001
6	Severity score 1 vs. 2–4	79.4	38.3–164.8	.534	32.9	15.4–70.5	.005
9	Severity score 1 vs. 2–4	40.8	22.6–73.8	.003	29.0	12.1–69.5	.006
1	SOTRs vs. controls	20.7	8.7–49.0	<.001	20.3	6.7–61.6	.005
3	SOTRs vs. controls	28.9	17.4–48.1	<.001	59.3	30.0–117.1	.131
6	SOTRs vs. controls	30.7	15.6–60.5	<.001	91.6	44.6–188.1	.809
9	SOTRs vs. controls	27.6	15.5–49.2	<.001	56.5	25.1–127.0	.165

Note: An analysis of clinical factors predicting antibody response utilizing a mixed model for repeated measures (MMRM). The model utilizes all serological data points regardless of a corresponding data point being available in the matched control. SOTRs vs. controls adjusted for age, sex, and COVID-19 severity score. Estimated ratio refers to the difference in antibody levels between the first and the second comparison groups. Severity score was defined according to the NIH criteria (1: mild, 2: moderate, 3: severe, 4: critical).

Values in bold are considered statistically significant with a p value <.05.

Abbreviations: AZA, azathioprine; MMF, mycophenolate mofetil.